Postmenopausal Osteoporosis Treatment Discontinued

The discontinuation of Miacalcin Nasal Spray is not due to the product's safety, efficacy or quality
The discontinuation of Miacalcin Nasal Spray is not due to the product's safety, efficacy or quality

The Food and Drug Administration (FDA) has posted a discontinuation notice for Miacalcin Nasal Spray (calcitonin-salmon; Mylan).

Miacalcin Nasal Spray is a polypeptide hormone indicated to treat postmenopausal osteoporosis. The 200 IU/spray multi-dose container with pump has been discontinued; this is not due to the product's safety, efficacy or quality.  

Related Articles

Calcitonin acts primarily on the bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action.

Miacalcin is also available as a 200 IU/mL strength injection. This formulation is indicated to treat Paget's disease of bone, hypercalcemia, and postmenopausal osteoporosis in women >5 years postmenopausal. 

For more information call (800) 796-9526 or visit Mylan.com.